Title: Immunohistochemical Expression of PD-L1 in Colorectal Carcinoma Among Black
Patients and the Clinicopathological Correlates: A Cross-Sectional Study
Version: 2 Date: 28 Feb 2025
Reviewer's report:
1. Last sentence in the background of the abstract (using the chi-square …………………
significant) may be removed.
2. In the study site, please simplify. Page 5, lines 12 to 15 (with a population
…………………………….Onitcha) are unnecessary details.
3. Please clarify why 96 cases only are selected from the 133 colorectal specimens (Page 6,
line 10).
4. Please clarify the cause of using TPS score and not using CPS score for PDL1 scoring (page 6).
5. The positive PDL1 immunostaining was divided into low and high staining (page 6). What
is your reference for this point.
6. Why there are 16 cases not applicable for grading (Table 1).
7. Please mention the staging system you depended on for staging of the cases.
8. The sentence (page 12, line 2) is inappropriate.
9. Please mention the name of the test used in the bottom of table 2.
10. The sentence in the conclusion, page 18, line 9-11 (furthermore ………………prognosis)
is out of your current work.
Title: Immunohistochemical Expression of PD-L1 in Colorectal Carcinoma Among Black
Patients and the Clinicopathological Correlates: A Cross-Sectional Study
Version: 2 Date: 28 Feb 2025
Reviewer's report:
1. Last sentence in the background of the abstract (using the chi-square …………………
significant) may be removed.
2. In the study site, please simplify. Page 5, lines 12 to 15 (with a population
…………………………….Onitcha) are unnecessary details.
3. Please clarify why 96 cases only are selected from the 133 colorectal specimens (Page 6,
line 10).
4. Please clarify the cause of using TPS score and not using CPS score for PDL1 scoring (page 6).
5. The positive PDL1 immunostaining was divided into low and high staining (page 6). What
is your reference for this point.
6. Why there are 16 cases not applicable for grading (Table 1).
7. Please mention the staging system you depended on for staging of the cases.
8. The sentence (page 12, line 2) is inappropriate.
9. Please mention the name of the test used in the bottom of table 2.
10. The sentence in the conclusion, page 18, line 9-11 (furthermore ………………prognosis)
is out of your current work.
Please review this paper.
user
Title: Immunohistochemical Expression of PD-L1 in Colorectal Carcinoma Among Black
Patients and the Clinicopathological Correlates: A Cross-Sectional Study
Version: 2 Date: 28 Feb 2025
Reviewer's report:
1. Last sentence in the background of the abstract (using the chi-square …………………
significant) may be removed.
2. In the study site, please simplify. Page 5, lines 12 to 15 (with a population
…………………………….Onitcha) are unnecessary details.
3. Please clarify why 96 cases only are selected from the 133 colorectal specimens (Page 6,
line 10).
4. Please clarify the cause of using TPS score and not using CPS score for PDL1 scoring (page 6).
5. The positive PDL1 immunostaining was divided into low and high staining (page 6). What
is your reference for this point.
6. Why there are 16 cases not applicable for grading (Table 1).
7. Please mention the staging system you depended on for staging of the cases.
8. The sentence (page 12, line 2) is inappropriate.
9. Please mention the name of the test used in the bottom of table 2.
10. The sentence in the conclusion, page 18, line 9-11 (furthermore ………………prognosis)
is out of your current work.
assistant